Overview

Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)

Status:
Completed
Trial end date:
2001-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the percentage of subjects who reach the target HbA1c level (< or = 7.0% at endpoint) and do not experience symptomatic nocturnal hypoglycemia during treatment with insulin glargine or NPH human insulin.
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Hypoglycemic Agents
Insulin
Insulin Glargine
Insulin, Globin Zinc
Insulin, Isophane
Isophane insulin, beef
Isophane Insulin, Human